A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 04 Oct 2018 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
- 04 Oct 2018 Planned primary completion date changed from 1 Sep 2021 to 1 Oct 2021.
- 04 Oct 2018 Status changed from not yet recruiting to recruiting.